Document Detail

Clinical manifestation of gadodiamide-related nephrogenic systemic fibrosis.
MedLine Citation:
PMID:  18397714     Owner:  NLM     Status:  MEDLINE    
AIMS: To further characterize the clinical signs and symptoms of nephrogenic systemic fibrosis, a new and serious disease affecting renal failure patients and caused by some Gd-containing contrast agents, including gadodiamide. MATERIAL: 22 cases of gadodiamide-related nephrogenic systemic fibrosis followed at the nephrology department of Copenhagen University Hospital Herlev. METHOD: Retrospective cohort study based on medical records, personal interviews and physical examinations. RESULTS: Typical first signs of the disease were skin discoloration, induration and warmth, itching, constant pain and other neuropathic symptoms localized to the lower legs. First sign appeared in a median of 14 days (range 0 â 53 days) after gadodiamide exposure. Associated early symptoms included sleeplessness and transient, diffuse hair loss. The predominant late symptom was symmetrical skin stiffness of extremities with or without restricted joint motion. Ten of 22 patients (45, 95% CI: 27 â 66%) were severely disabled due to contractures on the average of 29 months after being exposed to gadodiamide. Four patients died (18, 95% CI: 6 â 41). Patients perceived that intensive physiotherapy was effective in limiting disabling contractures. CONCLUSIONS: Signs and symptoms of nephrogenic systemic fibrosis vary over time and between patients. The disease leads to severe disability in a significant proportion of affected patients. Intensive physiotherapy may limit the development of contractures.
P Marckmann; L Skov; K Rossen; H S Thomsen
Related Documents :
6502444 - Sweet sorrow: the color-shading response in an adult cystic fibrosis population.
20179644 - Association of the clca1 p.s357n variant with meconium ileus in european patients with ...
15296904 - Comparative analysis of t2 selective division of rami-communicantes (ramicotomy) with t...
6422844 - Cefsulodin sodium therapy in cystic fibrosis patients.
127954 - Sjogren's syndrome and drug reaction to practalol.
7481984 - Sequential endoscopic/laparoscopic management of sickle hemoglobinopathy-associated cho...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical nephrology     Volume:  69     ISSN:  0301-0430     ISO Abbreviation:  Clin. Nephrol.     Publication Date:  2008 Mar 
Date Detail:
Created Date:  2008-04-09     Completed Date:  2008-06-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0364441     Medline TA:  Clin Nephrol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  161-8     Citation Subset:  IM    
Department of Nephrology, Copenhagen University Hospital Herlev, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Contrast Media / administration & dosage,  adverse effects*
Fibrosis / chemically induced
Follow-Up Studies
Gadolinium DTPA / administration & dosage,  adverse effects*,  diagnostic use
Glomerular Filtration Rate / drug effects
Injections, Intravenous
Kidney Failure, Chronic / chemically induced,  pathology*,  physiopathology
Middle Aged
Retrospective Studies
Severity of Illness Index
Reg. No./Substance:
0/Contrast Media; 122795-43-1/gadodiamide; 80529-93-7/Gadolinium DTPA

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hepatitis C virus-related kidney disease: an overview.
Next Document:  Renal protection in diabetes: is it affected by glucose control or inhibition of the renin-angiotens...